ERBB2 and invasive ductal breast carcinoma: Last, we tested clinical factors (pathologic stage, grade, tumor size (pT), node status (pN), luminal subtype A vs B, progesterone receptor (PR) status, ERBB2 status, Ki‐67 status, and invasive ductal adenocarcinomas vs others, menopause status).